Universal markers of thyroid malignancies: Galectin-3, HBME-1, and Cytokeratin-19

Endocrine Pathology

Volumn 21, Issue 2, 2010, Pages 80-89

  Barut, Figen ^a   Kandemir, Nilufer Onak ^a   Bektas, Sibel ^a   Bahadir, Burak ^a   Keser, Sevinc ^b   Ozdamar, Sukru Oguz ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Dr Lutfi Kirdar Kartal Research and Training Hospital   (Turkey)

Author keywords

Cytokeratin 19; Differential diagnosis; Galectin 3; HBME 1; Thyroid lesions

Indexed keywords

AVIDIN; BIOTIN; CELL SURFACE PROTEIN; CYTOKERATIN 19; FORMALDEHYDE; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL CELL 1; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG; HBME 1 ANTIGEN; HBME-1 ANTIGEN; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MARKER GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; BIOSYNTHESIS; GENETICS; METABOLISM; THYROID DISEASE; THYROID TUMOR;

DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; SENSITIVITY AND SPECIFICITY; THYROID DISEASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955887692     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-010-9114-y     Document Type: Article

References (35)

1. Schelfhout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol 92:654-8, 1989.
2. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said S, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122:524-31, 2004.
3. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22:621-8, 2007.
4. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3:5, 2008.
5. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48-57, 2005.
6. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immuno-histochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338-42, 2001.
7. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 19:92-6, 2008.
8. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin-19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47:391-401, 2005.
9. Beesley MF, McLaren KM. Cytokeratin-19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41:236-43, 2002.
10. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, et al. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin-19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci 20:853-9, 2005.
11. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol 15:2811-26, 2008.
12. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immu-nohistochemical tissue microarray analysis. Endocr Pathol 17:225-34, 2006.
13. Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541-6, 2005.
14. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58:3015-20, 1998.
15. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475-84, 1999.
16. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31:428-33, 2000.
17. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. and the Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-50, 2001.
18. Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, et al. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 87:4792-6, 2002.
19. Kovàcs RB, Földes J, Winkler G, Bodò M, Sàpi Z. The investigation of galectin-3 in diseases of thyroid gland. Eur J Endocrinol 149:449-53, 2003.
20. Volante M, Bozzalla-Cassione F, Orlandi F, Papotti M. Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch 444:309-12, 2004.
21. Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, et al. Expression of galectin-3 and galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med J 49:333-8, 2008.
22. Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 26:960-6, 2004.
23. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, et al. Galectin-3 expression in follicular tumours: an immunohis-tochemical study of its use as a marker of follicular carcinoma. Pathology 37:296-8, 2005.
24. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 47:209-14, 2005.
25. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 105:87-95, 2005.
26. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, et al. Characterization of thyroid "follicular neoplasms" in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12:305-17, 2005.
27. Castro R, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 142:926-31, 2005.
28. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations expresses molecular markers of PTC. Histopathology 45:39-46, 2004.
29. Erkiliç S, Aydin A, Koçer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol 13:207-11, 2002.
30. Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M. Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 430:239-45, 1997.
31. DeLellis RA, Williams ED. Thyroid and parathyroid tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World health organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
32. Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48:795-800, 2006.
33. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700-8, 2006.
34. Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50:173-7, 2003.
35. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immuno-histochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 19:1631-7, 2006.